Exicure stock fell 3.77 percent on October 1 as Nasdaq deadline nears

Published on 10/07/2026 at 06:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exicure must restore USD 2.5 million in stockholders' equity by December 2, 2026, under a Nasdaq extension. Its USD 7.46 million market value leaves the listing deadline central.

XCUR, US30205M3097, Illustration mit AI erstellt.

Exicure stock (ISIN US30205M3097) fell 3.77 percent to USD 1.15 on Nasdaq on October 1, 2026, with the move placing the small biotechnology company near the lower end of its yearly trading range. The next major checkpoint is December 2, 2026, when Exicure must demonstrate compliance with Nasdaq's stockholders' equity requirement.

Nasdaq deadline sets the key test

According to GlobeNewswire on September 16, 2026, Exicure received an extension after Nasdaq granted additional time on September 10, 2026. The company must regain compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least USD 2.5 million in stockholders' equity.

The extension gives Exicure until December 2, 2026, to complete its compliance initiatives and publicly demonstrate that it meets the requirement. As StockTitan reports from the September 16, 2026 filing, Nasdaq may issue a written delisting determination if the terms are not satisfied, subject to an appeal to a Nasdaq Hearings Panel.

Small market value sharpens the pressure

Exicure's market capitalization was USD 7.46 million on October 1, 2026, while the stock's 52-week range was USD 1.05 to USD 9.48. The October 1 price of USD 1.15 therefore stood USD 8.33 below the yearly high, a 87.87 percent gap calculated from the quoted values.

Trading activity also underscored the stock's limited scale on October 1, 2026. Volume was 2,360 shares against an average volume of 402,030 shares, leaving the session at 99.41 percent below that average and making individual price changes sensitive to limited trading activity.

Biotechnology strategy remains asset focused

Exicure describes itself as a biotechnology company pursuing strategic initiatives intended to strengthen its financial position, maximize the value of its assets and establish a foundation for future investment and business growth, according to GlobeNewswire on September 16, 2026.

For investors, the listing deadline and the equity threshold matter more immediately than a conventional growth narrative. The combination of a USD 7.46 million market value, a USD 1.15 share price and the USD 2.5 million Nasdaq requirement leaves compliance progress as the clearest dated company-specific checkpoint.

Exicure stock faces a December test

Exicure stock was last quoted at USD 1.15 on Nasdaq on October 1, 2026. Its next dated corporate checkpoint is December 2, 2026, when the company must demonstrate compliance with the stockholders' equity requirement.